ExploreWatchlistsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Income before tax

LIGAND PHARMACEUTICALS INC (LGND)

Market cap
$4.7B
P/E ratio
38.2x
SummaryFinancials
Period EndIncome before tax (Million USD)YoY (%)
Dec 31, 2025159+6212.95%
Dec 31, 20243-96.04%
Dec 31, 202364+76.78%
Dec 31, 202236-23.86%
Dec 31, 202147-548.83%
Dec 31, 2020-11-101.32%
Dec 31, 2019797+359.61%
Dec 31, 2018173+202.86%
Dec 31, 201757+618.98%
Dec 31, 20168-77.47%
Dec 31, 201535+212.59%
Dec 31, 201411+22.77%
Dec 31, 20139-338.19%
Dec 31, 2012-4+30.93%
Dec 31, 2011-3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat